Regenxbio Inc (NASDAQ: RGNX) on Monday, soared 5.40% from the previous trading day, before settling in for the closing price of $9.63. Within the past 52 weeks, RGNX’s price has moved between $8.53 and $28.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 72.63% over the past five years. The company achieved an average annual earnings per share of 21.64%. With a float of $44.84 million, this company’s outstanding shares have now reached $49.55 million.
Let’s look at the performance matrix of the company that is accounted for 344 employees. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.
Regenxbio Inc (RGNX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Regenxbio Inc is 9.50%, while institutional ownership is 90.26%. The most recent insider transaction that took place on Oct 01 ’24, was worth 101,052. In this transaction Director of this company sold 10,000 shares at a rate of $10.11, taking the stock ownership to the 11,286 shares. Before that another transaction happened on Sep 03 ’24, when Company’s Director sold 10,000 for $11.56, making the entire transaction worth $115,588. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.43 earnings per share (EPS) for the period falling under the consensus outlook (set at -1.28) by -0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.64% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Regenxbio Inc (RGNX) is currently performing well based on its current performance indicators. A quick ratio of 3.05 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Regenxbio Inc (NASDAQ: RGNX) saw its 5-day average volume 1.37 million, a positive change from its year-to-date volume of 0.62 million. As of the previous 9 days, the stock’s Stochastic %D was 45.37%. Additionally, its Average True Range was 0.92.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 23.66%, which indicates a significant decrease from 43.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.58% in the past 14 days, which was higher than the 70.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.47, while its 200-day Moving Average is $14.31. Nevertheless, the first resistance level for the watch stands at $11.04 in the near term. At $11.94, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.49. If the price goes on to break the first support level at $9.59, it is likely to go to the next support level at $9.04. Assuming the price breaks the second support level, the third support level stands at $8.14.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
Market capitalization of the company is 434.72 million based on 49,545K outstanding shares. Right now, sales total 90,240 K and income totals -263,490 K. The company made 24,200 K in profit during its latest quarter, and -59,600 K in sales during its previous quarter.
